University of Tennessee Cancer Institute SC-2 is a clinical research site located in Memphis, Tennessee, United States 38104.
Crixeo Clinical Trials Trust Score: 93/100 (GOOD). This profile has not yet been claimed by the site owner.
University of Tennessee Cancer Institute SC-2 has participated in 2 clinical trials.
Therapeutic areas: Relapsed or Refractory Multiple Myeloma, Diffuse Large B-cell Lymphoma.
Sponsors: Novartis Pharmaceuticals.
Is this your site? Claim your profile and control the information sponsors and patients see.
Browse all research sites in Tennessee · View every site in Memphis
Trust Score: 93/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
University of Tennessee Cancer Institute SC-2 has a Crixeo Trust Score of 93/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
University of Tennessee Cancer Institute SC-2 has 2 clinical trials on record. Their work covers Relapsed or Refractory Multiple Myeloma, Diffuse Large B-cell Lymphoma.
University of Tennessee Cancer Institute SC-2 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.